Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 8/20 | 0.50 |
| ▸ | HTR2C | P28335 | 8/20 | 0.50 |
| ▸ | HTR2B | P41595 | 7/20 | 0.50 |
| ▸ | EIF2AK3 | Q9NZJ5 | 2/20 | 0.46 |
| ▸ | SMO | Q99835 | 2/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.43 |
| ▸ | MTTP | P55157 | 2/20 | 0.42 |
| ▸ | APOB | P04114 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6489395 | 1.00 | HTR2A (0.50) | HTR2AHTR2CHTR2BEIF2AK3SMO | |
| SCHEMBL6488120 | 1.00 | HTR2A (0.50) | HTR2AHTR2CHTR2BEIF2AK3SMO | |
| SCHEMBL6489031 | 0.99 | HTR2A (0.51) | HTR2AHTR2CHTR2BEIF2AK3SMO | |
| SCHEMBL6492599 | 0.98 | HTR2A (0.51) | HTR2AHTR2CHTR2BEIF2AK3SMO | |
| SCHEMBL6489804 | 0.90 | EIF2AK3 (0.48) | HTR2AHTR2CHTR2BEIF2AK3 | |
| SCHEMBL6692999 | 0.90 | EIF2AK3 (0.45) | HTR2AHTR2CHTR2BEIF2AK3SMO | |
| SCHEMBL6490739 | 0.90 | EIF2AK3 (0.49) | HTR2AHTR2CHTR2BEIF2AK3RIPK1 | |
| SCHEMBL6499110 | 0.90 | EIF2AK3 (0.49) | HTR2AHTR2CHTR2BEIF2AK3RIPK1 | |
| SCHEMBL6490743 | 0.90 | EIF2AK3 (0.49) | HTR2AHTR2CHTR2BEIF2AK3RIPK1 | |
| SCHEMBL6500118 | 0.89 | HTR2C (0.49) | HTR2AHTR2CHTR2BEIF2AK3RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1472226-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003045921-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | HTR2A 659/4885HTR2C 1453/4885HTR2B 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.